Search results
The most innovative Mother’s Day campaigns from Dove, MoneyGram, DoorDash & more
The Drum· 4 days agoFrom heartwarming reunions facilitated by DoorDash to MullenLowe planting career opportunities for...
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines
GuruFocus.com via Yahoo Finance· 3 days agoExpenses: Reduced to $3.0 million in Q1 2024 from $4.2 million in Q1 2023, driven by lower costs across multiple programs. Partnership Developments: Established a new services agreement with ...
Vacaville man is MTC's Solano County Bike Champion of the Year
Fairfield-Suisun Daily Republic· 7 days agoEduardo "Eddie" Sanchez is the Metropolitan Transportation Committee's Solano County's Bike Champion...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 7 days agoFirst-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of
Recursion's BioHive-2, Powered by NVIDIA GPUs, Joins World's Top 35 Supercomputers
Analytics India Magazine· 18 hours agoBioHive-2 integrates 504 NVIDIA H100 Tensor Core GPUs within an NVIDIA Quantum-2 InfiniBand network, achieving a staggering two exaflops of AI performance.
Q1 2024 Matinas BioPharma Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoWhile we work to secure MAT2203 future. We are grateful to our new investors for their support. Keith? Keith Kucinski Thank you, Jerry, and good afternoon. In reviewing our financial performance ...
High costs, investor exit prompt closure of cell therapy biotech Walking Fish
FierceBiotech· 6 days agoWalking Fish Therapeutics has closed after a lead investor backed out of a critical series B round....
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
Morningstar· 4 days agoOn track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, ...
Curis to Present Updated Data from the TakeAim Leukemia Study
WPRI Providence· 4 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company ...
JD Supra: Biomedical Device Consultants and Laboratories of Colorado, LLC v. Vivitro Labs, Inc.
JD Supra· 5 days agoA preliminary injunction is one of the most potent weapons in a patent plaintiff's arsenal, being capable of shutting down an accused infringer's continued infringement, prohibiting the infringing ...
